[Source: PLoS One, full page: (LINK). Abstract, edited.]
OPEN ACCESS / PEER-REVIEWED / RESEARCH ARTICLE
Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program
Mark G. Wise , Mark A. Estabrook, Daniel F. Sahm, Gregory G. Stone, Krystyna M. Kazmierczak
Published: April 2, 2018 / DOI: https://doi.org/10.1371/journal.pone.0195281
A set of 908 clinically derived colistin-resistant Enterobacteriaeae isolates collected worldwide in 2014–2016 were screened for the presence of the plasmid-borne mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 genes. In total 3.2% (29/908) of the collection were positive for mcr, including 27 Escherichia coli, 1 Klebsiella pneumoniae and 1 Enterobacter cloacae. Twenty-four isolates possessed genes from the mcr-1 family, including the original mcr-1 (n = 22), as well as mcr-1.2 (n = 1) and mcr-1.5 (n = 1), which each differ from mcr-1 by encoding single amino acid variations. Genes from the mcr-3 family were found in isolates from Thailand, including mcr-3.1 (n = 3) and mcr-3.2 (n = 1). An E. coli isolated from a patient with a urinary tract infection in Colombia contained the recently discovered mcr-5. The full colistin-resistant collection was tested against a panel of antimicrobial agents with ceftazidime-avibactam and tigecycline exhibiting the highest activity.
Citation: Wise MG, Estabrook MA, Sahm DF, Stone GG, Kazmierczak KM (2018) Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program. PLoS ONE 13(4): e0195281. https://doi.org/10.1371/journal.pone.0195281
Editor: Yung-Fu Chang, Cornell University, UNITED STATES
Received: December 13, 2017; Accepted: March 19, 2018; Published: April 2, 2018
Copyright: © 2018 Wise et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are contained within the manuscript.
Funding: All work was performed at IHMA and sponsored by AstraZeneca Pharmaceuticals, LP, which also included compensation fees for manuscript preparation. AstraZeneca’s rights to ceftazidime-avibactam were acquired by Pfizer in December 2016.
Competing interests: All work was performed at IHMA and sponsored by AstraZeneca Pharmaceuticals, LP, which also included compensation fees for manuscript preparation. AstraZeneca’s rights to ceftazidime-avibactam were acquired by Pfizer in December 2016. G.S. was an employee of and shareholder in AstraZeneca Pharmaceuticals at the time of the study, and is currently an employee of Pfizer. M.W., M.E., D.S. and K.K. are employees of IHMA which received funding from AstraZeneca for the conduct of the study and development of this manuscript. None of the IHMA authors have any personal financial interest in the study sponsor (AstraZeneca Pharmaceuticals, LP) to disclose. This does not alter our adherence to all PLOS ONE policies on sharing data and materials.
Keywords: Antibiotics; Drugs Resistance; Colistin; Enterobacteriaceae; Ceftazidime-Avibactam; Tigecycline.